Artificial Intelligence-driven Drug Development - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511243881

Publication Date:

November 26, 2024

Pages:

165

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Computing & Electronics [3]

Description:

Artificial intelligence (AI) has the potential to revolutionize the drug discovery process,
offering improved efficiency, accuracy, and speed.

The global market for Artificial Intelligence-driven Drug Development was estimated to be worth US$ 1366.3 million in 2023 and is forecast to a readjusted size of US$ 8890.4 million by 2030 with a CAGR of 30.7% during the forecast period 2024-2030
North American market for Artificial Intelligence-driven Drug Development was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Artificial Intelligence-driven Drug Development was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Artificial Intelligence-driven Drug Development was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Artificial Intelligence-driven Drug Development include IBM, Exscientia, Google(Alphabet), Microsoft, Atomwise, Schrodinger, Aitia, Insilico Medicine and NVIDIA, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Artificial Intelligence-driven Drug Development, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Artificial Intelligence-driven Drug Development by region & country, by Type, and by Application.
The Artificial Intelligence-driven Drug Development market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Artificial Intelligence-driven Drug Development.
Market Segmentation
By Company
IBM
Exscientia
Google(Alphabet)
Microsoft
Atomwise
Schrodinger
Aitia
Insilico Medicine
NVIDIA
XtalPi
BPGbio
Owkin
CytoReason
Deep Genomics
Cloud Pharmaceuticals
BenevolentAI
Cyclica
Verge Genomics
Valo Health
Envisagenics
Euretos
BioAge Labs
Iktos
BioSymetrics
Evaxion Biotech
Aria Pharmaceuticals
Segment by Type:
Hardware
Software
Service
Segment by Application
Early Drug Discovery
Preclinical Phase
Clinical Phase
Regulatory Approval
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Artificial Intelligence-driven Drug Development manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Artificial Intelligence-driven Drug Development in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Artificial Intelligence-driven Drug Development in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Artificial Intelligence-driven Drug Development Product Introduction
1.2 Global Artificial Intelligence-driven Drug Development Market Size Forecast
1.3 Artificial Intelligence-driven Drug Development Market Trends & Drivers
1.3.1 Artificial Intelligence-driven Drug Development Industry Trends
1.3.2 Artificial Intelligence-driven Drug Development Market Drivers & Opportunity
1.3.3 Artificial Intelligence-driven Drug Development Market Challenges
1.3.4 Artificial Intelligence-driven Drug Development Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Artificial Intelligence-driven Drug Development Players Revenue Ranking (2023)
2.2 Global Artificial Intelligence-driven Drug Development Revenue by Company (2019-2024)
2.3 Key Companies Artificial Intelligence-driven Drug Development Manufacturing Base Distribution and Headquarters
2.4 Key Companies Artificial Intelligence-driven Drug Development Product Offered
2.5 Key Companies Time to Begin Mass Production of Artificial Intelligence-driven Drug Development
2.6 Artificial Intelligence-driven Drug Development Market Competitive Analysis
2.6.1 Artificial Intelligence-driven Drug Development Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Artificial Intelligence-driven Drug Development Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Artificial Intelligence-driven Drug Development as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Hardware
3.1.2 Software
3.1.3 Service
3.2 Global Artificial Intelligence-driven Drug Development Sales Value by Type
3.2.1 Global Artificial Intelligence-driven Drug Development Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Artificial Intelligence-driven Drug Development Sales Value, by Type (2019-2030)
3.2.3 Global Artificial Intelligence-driven Drug Development Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Early Drug Discovery
4.1.2 Preclinical Phase
4.1.3 Clinical Phase
4.1.4 Regulatory Approval
4.2 Global Artificial Intelligence-driven Drug Development Sales Value by Application
4.2.1 Global Artificial Intelligence-driven Drug Development Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Artificial Intelligence-driven Drug Development Sales Value, by Application (2019-2030)
4.2.3 Global Artificial Intelligence-driven Drug Development Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Artificial Intelligence-driven Drug Development Sales Value by Region
5.1.1 Global Artificial Intelligence-driven Drug Development Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Artificial Intelligence-driven Drug Development Sales Value by Region (2019-2024)
5.1.3 Global Artificial Intelligence-driven Drug Development Sales Value by Region (2025-2030)
5.1.4 Global Artificial Intelligence-driven Drug Development Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
5.2.2 North America Artificial Intelligence-driven Drug Development Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
5.3.2 Europe Artificial Intelligence-driven Drug Development Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
5.4.2 Asia Pacific Artificial Intelligence-driven Drug Development Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
5.5.2 South America Artificial Intelligence-driven Drug Development Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
5.6.2 Middle East & Africa Artificial Intelligence-driven Drug Development Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Artificial Intelligence-driven Drug Development Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Artificial Intelligence-driven Drug Development Sales Value
6.3 United States
6.3.1 United States Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
6.3.2 United States Artificial Intelligence-driven Drug Development Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Artificial Intelligence-driven Drug Development Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
6.4.2 Europe Artificial Intelligence-driven Drug Development Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Artificial Intelligence-driven Drug Development Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
6.5.2 China Artificial Intelligence-driven Drug Development Sales Value by Type (%), 2023 VS 2030
6.5.3 China Artificial Intelligence-driven Drug Development Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
6.6.2 Japan Artificial Intelligence-driven Drug Development Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Artificial Intelligence-driven Drug Development Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
6.7.2 South Korea Artificial Intelligence-driven Drug Development Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Artificial Intelligence-driven Drug Development Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
6.8.2 Southeast Asia Artificial Intelligence-driven Drug Development Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Artificial Intelligence-driven Drug Development Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Artificial Intelligence-driven Drug Development Sales Value, 2019-2030
6.9.2 India Artificial Intelligence-driven Drug Development Sales Value by Type (%), 2023 VS 2030
6.9.3 India Artificial Intelligence-driven Drug Development Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 IBM
7.1.1 IBM Profile
7.1.2 IBM Main Business
7.1.3 IBM Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.1.4 IBM Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.1.5 IBM Recent Developments
7.2 Exscientia
7.2.1 Exscientia Profile
7.2.2 Exscientia Main Business
7.2.3 Exscientia Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.2.4 Exscientia Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.2.5 Exscientia Recent Developments
7.3 Google(Alphabet)
7.3.1 Google(Alphabet) Profile
7.3.2 Google(Alphabet) Main Business
7.3.3 Google(Alphabet) Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.3.4 Google(Alphabet) Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.3.5 Microsoft Recent Developments
7.4 Microsoft
7.4.1 Microsoft Profile
7.4.2 Microsoft Main Business
7.4.3 Microsoft Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.4.4 Microsoft Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.4.5 Microsoft Recent Developments
7.5 Atomwise
7.5.1 Atomwise Profile
7.5.2 Atomwise Main Business
7.5.3 Atomwise Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.5.4 Atomwise Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.5.5 Atomwise Recent Developments
7.6 Schrodinger
7.6.1 Schrodinger Profile
7.6.2 Schrodinger Main Business
7.6.3 Schrodinger Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.6.4 Schrodinger Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.6.5 Schrodinger Recent Developments
7.7 Aitia
7.7.1 Aitia Profile
7.7.2 Aitia Main Business
7.7.3 Aitia Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.7.4 Aitia Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.7.5 Aitia Recent Developments
7.8 Insilico Medicine
7.8.1 Insilico Medicine Profile
7.8.2 Insilico Medicine Main Business
7.8.3 Insilico Medicine Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.8.4 Insilico Medicine Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.8.5 Insilico Medicine Recent Developments
7.9 NVIDIA
7.9.1 NVIDIA Profile
7.9.2 NVIDIA Main Business
7.9.3 NVIDIA Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.9.4 NVIDIA Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.9.5 NVIDIA Recent Developments
7.10 XtalPi
7.10.1 XtalPi Profile
7.10.2 XtalPi Main Business
7.10.3 XtalPi Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.10.4 XtalPi Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.10.5 XtalPi Recent Developments
7.11 BPGbio
7.11.1 BPGbio Profile
7.11.2 BPGbio Main Business
7.11.3 BPGbio Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.11.4 BPGbio Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.11.5 BPGbio Recent Developments
7.12 Owkin
7.12.1 Owkin Profile
7.12.2 Owkin Main Business
7.12.3 Owkin Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.12.4 Owkin Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.12.5 Owkin Recent Developments
7.13 CytoReason
7.13.1 CytoReason Profile
7.13.2 CytoReason Main Business
7.13.3 CytoReason Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.13.4 CytoReason Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.13.5 CytoReason Recent Developments
7.14 Deep Genomics
7.14.1 Deep Genomics Profile
7.14.2 Deep Genomics Main Business
7.14.3 Deep Genomics Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.14.4 Deep Genomics Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.14.5 Deep Genomics Recent Developments
7.15 Cloud Pharmaceuticals
7.15.1 Cloud Pharmaceuticals Profile
7.15.2 Cloud Pharmaceuticals Main Business
7.15.3 Cloud Pharmaceuticals Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.15.4 Cloud Pharmaceuticals Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.15.5 Cloud Pharmaceuticals Recent Developments
7.16 BenevolentAI
7.16.1 BenevolentAI Profile
7.16.2 BenevolentAI Main Business
7.16.3 BenevolentAI Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.16.4 BenevolentAI Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.16.5 BenevolentAI Recent Developments
7.17 Cyclica
7.17.1 Cyclica Profile
7.17.2 Cyclica Main Business
7.17.3 Cyclica Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.17.4 Cyclica Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.17.5 Cyclica Recent Developments
7.18 Verge Genomics
7.18.1 Verge Genomics Profile
7.18.2 Verge Genomics Main Business
7.18.3 Verge Genomics Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.18.4 Verge Genomics Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.18.5 Verge Genomics Recent Developments
7.19 Valo Health
7.19.1 Valo Health Profile
7.19.2 Valo Health Main Business
7.19.3 Valo Health Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.19.4 Valo Health Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.19.5 Valo Health Recent Developments
7.20 Envisagenics
7.20.1 Envisagenics Profile
7.20.2 Envisagenics Main Business
7.20.3 Envisagenics Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.20.4 Envisagenics Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.20.5 Envisagenics Recent Developments
7.21 Euretos
7.21.1 Euretos Profile
7.21.2 Euretos Main Business
7.21.3 Euretos Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.21.4 Euretos Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.21.5 Euretos Recent Developments
7.22 BioAge Labs
7.22.1 BioAge Labs Profile
7.22.2 BioAge Labs Main Business
7.22.3 BioAge Labs Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.22.4 BioAge Labs Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.22.5 BioAge Labs Recent Developments
7.23 Iktos
7.23.1 Iktos Profile
7.23.2 Iktos Main Business
7.23.3 Iktos Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.23.4 Iktos Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.23.5 Iktos Recent Developments
7.24 BioSymetrics
7.24.1 BioSymetrics Profile
7.24.2 BioSymetrics Main Business
7.24.3 BioSymetrics Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.24.4 BioSymetrics Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.24.5 BioSymetrics Recent Developments
7.25 Evaxion Biotech
7.25.1 Evaxion Biotech Profile
7.25.2 Evaxion Biotech Main Business
7.25.3 Evaxion Biotech Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.25.4 Evaxion Biotech Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.25.5 Evaxion Biotech Recent Developments
7.26 Aria Pharmaceuticals
7.26.1 Aria Pharmaceuticals Profile
7.26.2 Aria Pharmaceuticals Main Business
7.26.3 Aria Pharmaceuticals Artificial Intelligence-driven Drug Development Products, Services and Solutions
7.26.4 Aria Pharmaceuticals Artificial Intelligence-driven Drug Development Revenue (US$ Million) & (2019-2024)
7.26.5 Aria Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Artificial Intelligence-driven Drug Development Industrial Chain
8.2 Artificial Intelligence-driven Drug Development Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Artificial Intelligence-driven Drug Development Sales Model
8.5.2 Sales Channel
8.5.3 Artificial Intelligence-driven Drug Development Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

IBM
Exscientia
Google(Alphabet)
Microsoft
Atomwise
Schrodinger
Aitia
Insilico Medicine
NVIDIA
XtalPi
BPGbio
Owkin
CytoReason
Deep Genomics
Cloud Pharmaceuticals
BenevolentAI
Cyclica
Verge Genomics
Valo Health
Envisagenics
Euretos
BioAge Labs
Iktos
BioSymetrics
Evaxion Biotech
Aria Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂